Considering growing concerns with neoadjuvant therapy in HER2 + BC, we here made a retrospective analysis to evaluate PR status as a predictor of response to neoadjuvant dual anti-HER2 therapy in HER2 + /N + breast cancer and provide real-world data to further explore pertuzumab-containing neoadjuvant treatment patterns. This evidence concerns the gene ERBB2 and breast carcinoma.